Naegleria fowleri, commonly known as the "brain-eating amoeba," is a free-living, thermophilic protozoan that belongs to the phylum Percolozoa. This deadly pathogen causes primary amebic meningoencephalitis (PAM), which is a rare yet rapidly fatal infection of the central nervous system. N fowleri thrives in warm freshwater environments, such as lakes, rivers, and poorly chlorinated pools, and usually enters the body through the nasal passages during water-related activities. Infection occurs when contaminated water enters the nasal passages, allowing the amoeba to migrate to the brain. This causes severe inflammation and necrosis, leading to a nearly universal mortality rate if not diagnosed and treated promptly.
Diagnosis is challenging due to nonspecific symptoms resembling viral or bacterial infections. Prompt recognition, accurate diagnosis, and aggressive combination therapy are crucial for improving outcomes, although survival remains rare. This activity provides an in-depth review of N fowleri, covering its epidemiology, pathophysiology, clinical presentation, diagnostic challenges, and current treatment strategies. This activity also emphasizes the importance of collaboration and the critical role of the interprofessional healthcare team in promptly identifying, diagnosing, and managing PAM to initiate appropriate interventions and improve patient outcomes.
Objectives:
Identify the early symptoms of primary amebic meningoencephalitis caused by Naegleria fowleri, including fever, headache, and nausea, to improve early recognition.Differentiate Naegleria fowleri infections from bacterial, viral, and other protozoal central nervous system infections based on cerebrospinal fluid analysis, imaging, and clinical history.Apply current treatment guidelines for managing primary amebic meningoencephalitis, including antimicrobial therapy and supportive care, to initiate prompt treatment.Collaborate with the interprofessional healthcare team, including interventional radiologists, infectious disease specialists, neurologists, and intensivists, to ensure comprehensive care for patients with PAM. Access free multiple choice questions on this topic. IntroductionNaegleria fowleri is a free-living, eukaryotic amoeba belonging to the genus Naegleria and is commonly known as the "brain-eating amoeba."[1] N fowleri is a facultative parasite, meaning it does not require a host to complete its life cycle and reproduces by mitosis.[2] The 4 free-living amoebae—N fowleri, Balamuthia mandrillaris, Sappinia spp, and Acanthamoeba spp—are responsible for human amebic meningoencephalitis, which are severe and often fatal infections of the central nervous system (CNS).[2][3]
Of the 47 species of Naegleria, only N fowleri causes primary amebic meningoencephalitis (PAM), which is a rare but rapidly progressing and almost always fatal CNS infection, leading to the death of patients within 3 to 7 days.[4][5] N fowleri was named after Malcolm Fowler, who first documented a case of PAM in Australia.[6]
N fowleri is a thermophilic amoeba that thrives in temperatures up to 45 °C and is commonly found in warm freshwater environments, including soil, lakes, and rivers. This amoeba can also be present in inadequately chlorinated water, such as swimming pools and tap water.[7][8]
N fowleri causes PAM when contaminated freshwater enters the nasal passages, usually during activities such as swimming in freshwater bodies, using poorly chlorinated pools, or performing nasal rinses with nonsterile water.[9] After entering the nose, the amoeba migrates along the olfactory nerves, crosses the cribriform plate, and invades the CNS, resulting in PAM. The infection is characterized by cerebral edema, hemorrhagic necrosis, brain herniation, and, in most cases, death.[4]
PAM is challenging to diagnose clinically, as its initial symptoms are nonspecific and can resemble flu-like illness, bacterial meningitis, or viral meningoencephalitis. A high index of suspicion is essential, and clinicians must be aware of the epidemiology and potential exposures to oid missed diagnoses. PAM progresses rapidly and is almost always fatal.[3]
Given the severity, high fatality rate, and limited treatment options of PAM, obtaining a thorough epidemiological history and maintaining clinician awareness are crucial for prompt diagnosis and timely administration of ailable therapies.[3] Early recognition and intervention offer the best chance of improving patient outcomes, although survival remains rare.
EtiologyN fowleri is the causative agent of PAM, which is a rare but rapidly progressive and usually fatal infection of the CNS.[4] Although Acanthamoeba spp and B mandrillaris are opportunistic pathogens that cause granulomatous amebic encephalitis in immunocompetent and immunocompromised individuals, N fowleri primarily affects healthy, immunocompetent children and young adults who he been exposed to contaminated freshwater.[10]
Widely distributed worldwide, N fowleri thrives in warm freshwater environments as a thermophilic ameboflagellate, growing at temperatures up to 45 °C. This amoeba is commonly found in soil, lakes, and rivers and can also persist in inadequately chlorinated water sources, such as swimming pools, tap water, and industrial wastewater.[7][8]
The life cycle of N fowleri consists of 3 stages—trophozoites, flagellates, and cysts. The trophozoite stage is the reproductive and invasive form responsible for human infection. As a thermophilic organism, it is most active during the warm summer when human exposure is more likely. Trophozoites are long and slender, approximately 22 µm long, equipped with pseudopodia for movement and bacterial ingestion, and capable of forming large colonies.[11]
Under poor nutritive conditions, trophozoites transition into flagellates by developing flagella.[11] If unforable conditions persist, they further transform into metabolically inactive cysts, measuring 7 to 12 μm. These cysts are highly resistant, capable of withstanding low temperatures, and can survive during winter.[11] Trophozoites feed on bacteria and fungi in warm waters and can encyst and settle into sediments when water temperatures drop during winter.[12]
Of the 47 known species of Naegleria, only N fowleri causes PAM, which is a rare but aggressive infection that typically leads to death within 3 to 7 days.[4][5] Infection occurs when contaminated water enters the nasal passages, usually through freshwater exposure or nasal rinsing with nonsterile water.[13] Once inside, N fowleri migrates to the CNS via the olfactory nerves and cribriform plate, leading to severe and nearly always fatal infection.[4] Notably, ingestion of N fowleri does not cause infection.
EpidemiologyN fowleri is ubiquitous and has been found worldwide in soil and freshwater environments, including lakes, hot water springs, poorly chlorinated pools, and thermally polluted water bodies.[7][14][15] Although cases of N fowleri PAM he been reported on all continents, the true incidence is likely underdiagnosed or underreported.[16] The disease has an incubation period of 1 to 14 days and progresses rapidly, presenting with nonspecific signs and symptoms. A high index of suspicion is essential for diagnosis, as mortality reaches 98%, with a median time from symptom onset to death of 5 days.[17] In many cases, death occurs before a diagnosis is made, and the disease is confirmed postmortem if an autopsy is performed.[16][18]
Diagnosing PAM requires specialized laboratory tests on cerebrospinal fluid (CSF) or brain tissue, which must be conducted promptly. However, many hospitals lack the necessary diagnostic resources. Establishing surveillance systems and classifying PAM as a notifiable disease would improve data collection and facilitate early recognition.
Globally, N fowleri infections are more prevalent in healthy, immunocompetent young males during the summer when water temperatures are high and people engage in outdoor water activities.[11] A recent study analyzing global epidemiological data from published and unpublished reports and the Centers for Disease Control and Prevention (CDC) Free-Living Ameba Surveillance System (1962–2018) identified 381 cases of PAM caused by N fowleri—157 from the United States and 223 from 32 other countries.[4] Of these, 182 cases were confirmed, 89 were probable, and 110 were suspect. The highest number of cases worldwide occurred in the United States, Pakistan, and Mexico.
In the United States, N fowleri has been responsible for 157 known cases from 1962 to 2022, with only 4 survivors.[17] Annually, 0 to 8 laboratory-confirmed cases are reported, and PAM accounts for fewer than 0.5% of diagnosed encephalitis-related deaths.[16] Historically, most N fowleri infections he been reported in southern states, particularly Florida, Texas, and southern California. However, recent cases he been detected in northern states, such as Maryland, Indiana, northern California, Connecticut, and Minnesota, potentially due to rising temperatures and increased waterborne exposure.[7][17][19]
Most N fowleri infections occur through recreational freshwater exposure, such as swimming or diving.[14] However, rare cases he been linked to household water use. In Arizona, 2 children contracted PAM while bathing at home, and N fowleri was traced to an untreated community well-water system.[20]
PathophysiologyN fowleri is a thermophilic amoeba that thrives in temperatures up to 45 °C and is widely distributed in warm freshwater environments. This amoeba is commonly found in soil, lakes, and rivers but can also persist in inadequately chlorinated water sources, such as swimming pools and tap water.[7][8]
N fowleri infection occurs when contaminated freshwater enters the nasal passages, typically during swimming in freshwater bodies, using poorly chlorinated pools, or performing nasal rinses with nonsterile water.[9] After entering through the nose, N fowleri migrates via the olfactory nerves, crosses the cribriform plate, and invades the CNS, thereby causing PAM. This infection is characterized by cerebral edema, hemorrhagic necrosis, herniation, and, in most cases, death.[4] The most severely affected regions of the brain include the olfactory bulbs, the basilar portion of the frontal cerebrum, and the cerebellum.
N fowleri triggers a strong innate immune response, and its virulence is influenced by multiple factors, including the protein Nfa1, nitric oxide production, and pore-forming proteins. The Nfa1 protein facilitates amebic attachment to target cells, while specialized feeding structures enable the amoeba to ingest bacteria and fungi in the environment and directly phagocytose brain cells. The organism further contributes to tissue destruction by secreting cytolytic molecules, including cysteine proteases, phospholipases, and phospholipolytic enzymes, which mediate extensive necrosis. This intense immune response and aggressive virulence of N fowleri result in significant destruction of brain parenchymal tissue, leading to the rapid progression of PAM.[21]
History and PhysicalA detailed patient history and thorough physical examination are crucial for diagnosing PAM. The disease is challenging to identify clinically, as its early symptoms are often nonspecific and can resemble flu-like illnesses, bacterial meningitis, or viral meningoencephalitis. Clinicians must maintain a high index of suspicion and be aware of epidemiological risk factors and potential exposures, as failure to recognize PAM can result in delayed diagnosis and rapid fatality.[3]
Given its severity, high fatality rate, and limited treatment options, obtaining an accurate epidemiological history is crucial. Clinician awareness is necessary for prompt diagnosis and the immediate initiation of ailable therapies.[3]
The incubation period for PAM ranges from 1 to 14 days. Early symptoms, such as fever, headache, lethargy, nausea, and vomiting, may resemble bacterial meningitis. As the disease progresses, more severe manifestations develop, including confusion, neck stiffness, photophobia, seizures, and cranial nerve abnormalities. In most cases, PAM progresses rapidly, leading to coma and death within a matter of days.
EvaluationDiagnosing PAM is challenging, as patients do not always present with the classic symptoms of meningitis. Early symptoms are often vague and nonspecific, resembling mild viral or bacterial infections. Patients may initially experience fever and headache, which can progress to meningismus and confusion, depending on the stage of the disease at the time of presentation.[22] Given its rapid progression and high fatality rate, PAM should be suspected in any patient with meningoencephalitis or meningitis who has a recent history of freshwater exposure.
Laboratory findings in PAM can be nonspecific. CSF analysis often mimics bacterial meningitis, showing low to normal glucose levels, elevated protein, and leukocytosis with a polymorphonuclear predominance. CSF pressures are typically elevated, with recorded values reaching up to 600 mm H2O in some cases.[1][22] However, standard laboratory tests may not be sufficient for diagnosis.
Rapid diagnosis is critical due to the aggressive nature of PAM. Few laboratories in the United States and worldwide can test for N fowleri. Even when specimens are sent to reference laboratories, the disease often progresses too quickly for the results to be clinically useful. If CSF is obtained, several diagnostic tests can help identify N fowleri. A quick method involves visualizing trophozoites directly using a wet mount. Staining techniques, including Giemsa, Wright, hematoxylin and eosin (H&E), and periodic acid–Schiff (PAS), can also be utilized.
Polymerase chain reaction (PCR) testing can detect N fowleri DNA directly from CSF and is now considered the gold standard for PAM diagnosis. However, PCR limitations include limited ailability and the necessity of clinical suspicion. Gram staining and standard bacterial cultures are unreliable, as the fixation process destroys the amoebae. Antigen detection via immunohistochemical staining can also be performed on CSF samples.[23][24]
Additional diagnostic techniques for tissue samples include immunohistochemical staining, indirect immunofluorescence, PCR, and culture. Serological testing is generally not useful, as PAM progresses too rapidly for results to be ailable before the patient’s death. Magnetic resonance imaging (MRI) may provide some insight, although findings are often nonspecific in the early stages. MRI may show diffuse hemorrhages, infarctions, or contrast enhancement in affected brain regions as the infection advances.
A brain biopsy, if feasible, can provide definitive evidence of PAM. Histopathological examination typically reveals hemorrhagic meningitis, with the base of the brain and olfactory bulbs being the most severely affected areas. Numerous trophozoites are often observed within the necrotic meninges.[3]
Metagenomic next-generation sequencing has recently gained attention as a promising diagnostic tool for free-living amoebae, including N fowleri.[17] This shotgun sequencing approach enables broad pathogen detection from CSF, tissue, and serum samples without requiring large specimen volumes. Microbial cell-free DNA analysis has also been explored for detecting free-living amoebae. A 2023 report identified cases of Acanthamoeba spp, B mandrillaris, and N fowleri between 2018 and 2021 using this technique.[25] These emerging sequencing technologies he the potential to reduce diagnostic delays and improve early detection, ultimately enhancing patient outcomes.
Treatment / ManagementTreatment options for PAM remain limited due to the lack of controlled trials or clinical studies. Current therapeutic approaches are based on in-vitro studies and case reports.[26][27][28][29]
The recommended treatment regimen typically involves a combination of 5 or 6 antimicrobial or antifungal agents that either demonstrate in-vitro activity against N fowleri or he been associated with survival in patients. Miltefosine is the most recent addition to this regimen, which commonly includes amphotericin B, azithromycin, fluconazole, rifampin, and dexamethasone. However, the efficacy of these drugs remains inconsistent, and their use is often linked to significant toxicity.[11][30]
Amphotericin B is the primary drug of choice for PAN, exhibiting amebicidal activity at low concentrations. This drug is recommended to be used in combination with at least one other amebicidal agent. The CDC advises the use of conventional amphotericin B over the liposomal formulation for both intrathecal and intrenous administration, as in-vitro studies indicate a higher minimum inhibitory concentration (MIC) for the liposomal formulation compared to conventional amphotericin B.[30]Miltefosine, originally developed as an antineoplastic agent for breast cancer, has shown promise in treating N fowleri infections. Notably, 2 patients who received miltefosine in 2013 and another in 2016 survived, marking a significant milestone in PAM treatment. Although miltefosine was initially accessible only through the CDC, it is now commercially ailable.[31][32]Azoles, such as fluconazole and voriconazole, penetrate the CNS effectively and are commonly used as adjunctive therapy with amphotericin B.Azithromycin has demonstrated in-vitro and in-vivo activity against N fowleri, with some studies suggesting a synergistic effect when combined with amphotericin B.[11]Rifampin exhibits amebicidal activity against N fowleri in vitro and enhances the effectiveness of amphotericin B when administered intrenously. It is commonly included in standard PAM therapy; however, clinicians should be mindful of potential drug-drug interactions. Rifampin induces hepatic cytochrome P450 enzymes, which can affect the metabolism of azoles and amphotericin B.Controlled hypothermia has been used in recent cases of PAM, with 3 children surviving the infection in 2013 and 2016 after receiving it as part of their treatment. These patients achieved full neurological recovery and were able to return to school, suggesting that controlled hypothermia may he a role in improving outcomes.[33][34]Differential DiagnosisPatients with PAM do not always exhibit the classic symptoms of meningitis, making diagnosis challenging. Early symptoms are often vague and nonspecific, resembling mild viral or bacterial infections. Patients may initially present with fever, headache, and general malaise, which can progress to meningismus and confusion depending on the disease's stage at presentation.[22]
PAM should be suspected in any patient presenting with meningoencephalitis or meningitis, particularly if there is a recent history of freshwater exposure. A thorough patient history is vital for identifying potential risk factors, and clinician awareness is essential for ensuring timely recognition and intervention.
PrognosisPAM is a rare but rapidly progressing disease with a poor prognosis, even when treatment is administered. N fowleri infection is associated with a mortality rate exceeding 98%, with a median time from symptom onset to death of just 5 days. Of the 157 reported cases in the United States between 1962 and 2022, only 4 patients survived.[17]
Diagnosing PAM is challenging due to limited awareness among healthcare professionals. The disease is rarely considered in the differential diagnosis, as its early symptoms resemble viral or bacterial meningoencephalitis and flu-like syndromes. Moreover, laboratory resources to confirm the diagnosis are often unailable. With no standardized, highly effective treatments, PAM remains nearly universally fatal.
ComplicationsN fowleri infection causes PAM, which is a rapidly progressive and often fatal disease. The infection leads to severe cerebral edema, hemorrhagic necrosis, and increased intracranial pressure, which can result in brain herniation and death within days of symptom onset. Other complications include seizures, cranial nerve dysfunction, hydrocephalus, and coma.
Due to its aggressive nature, PAM has a 98% mortality rate, with most patients succumbing despite treatment. Survivors may experience neurological deficits, although recovery is rare. Early diagnosis and prompt initiation of therapy are critical in preventing fatal outcomes and minimizing long-term complications.
ConsultationsManaging PAM requires a multidisciplinary approach. Specialists to consult include infectious disease physicians, neurologists, neuroradiologists, interventional radiologists, pharmacists, and intensivists, especially if a cerebral biopsy is needed.
Deterrence and Patient EducationTo prevent infection with N fowleri, individuals should oid activities that introduce fresh water into the nasal passages, especially during summer. When using non-sterile tap water or swimming in freshwater bodies or poorly chlorinated pools, it is important to keep the head above water or use nose clips.
For nasal irrigation, such as with a neti pot or during religious practices such as ablution, only sterile, distilled, filtered, or previously boiled water should be used.[35] Additionally, ensuring proper disinfection of water bodies, including swimming pools and public water systems with chlorination, can help prevent infection.[13][36]
Pearls and Other IssuesKey facts to keep in mind about N fowleri include:
N fowleri is a thermophilic, free-living amoeba found in warm freshwater bodies, such as lakes, hot springs, poorly chlorinated pools, or tap water.This amoeba is the causative agent of PAM.N fowleri enters the body through the nasal passages during activities such as swimming, diving, or nasal rinsing with contaminated water. This amoeba then crosses the cribriform plate and trels along the olfactory nerve to invade the central nervous system, causing rapidly progressive necrotizing meningoencephalitis.Early symptoms of N fowleri infection mimic viral or bacterial meningitis, including fever, headache, nausea, and vomiting. These symptoms rapidly progress to confusion, seizures, photophobia, meningismus, altered mental status, and coma.The disease is fatal in over 98% of cases, with a median survival of just 5 days after symptom onset.PCR is the gold standard for definitive diagnosis.CSF findings resemble those of bacterial meningitis, showing elevated white blood cells, low to normal glucose, elevated protein, and increased opening pressure.A wet mount will show motile trophozoites.Treatment involves a combination therapy, such as the administration of amphotericin B and miltefosine.Enhancing Healthcare Team OutcomesAccurate and timely diagnosis and management of PAM require coordinated effort and collaboration among an interprofessional healthcare team. Prompt consultation with an infectious disease specialist is crucial for effective treatment. Clinicians should also closely monitor patients and perform frequent assessments as the disease progresses rapidly.
Patients experiencing neurological deterioration and requiring mechanical ventilation should be managed in the intensive care unit (ICU) for optimal care. Additionally, collaboration with pharmacists is vital, as the medications used to treat PAM may he significant drug interactions that could reduce their therapeutic effectiveness.
Review Questions Access free multiple choice questions on this topic. Click here for a simplified version. Comment on this article. References1.Grace E, Asbill S, Virga K. Naegleria fowleri: pathogenesis, diagnosis, and treatment options. Antimicrob Agents Chemother. 2015 Nov;59(11):6677-81. [PMC free article: PMC4604384] [PubMed: 26259797]2.Zhang H, Cheng X. Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease. Front Med. 2021 Dec;15(6):842-866. [PubMed: 34825341]3.Kofman A, Guarner J. Infections Caused by Free-Living Amoebae. J Clin Microbiol. 2022 Jan 19;60(1):e0022821. [PMC free article: PMC8769735] [PubMed: 34133896]4.Gharpure R, Bliton J, Goodman A, Ali IKM, Yoder J, Cope JR. Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by Naegleria fowleri: A Global Review. Clin Infect Dis. 2021 Jul 01;73(1):e19-e27. [PMC free article: PMC8739754] [PubMed: 32369575]5.Vanden Esschert KL, Mattioli MC, Hilborn ED, Roberts VA, Yu AT, Lamba K, Arzaga G, Zahn M, Marsh Z, Combes SM, Smith ES, Robinson TJ, Gretsch SR, Laco JP, Wikswo ME, Miller AD, Tack DM, Wade TJ, Hlsa MC. Outbreaks Associated with Untreated Recreational Water - California, Maine, and Minnesota, 2018-2019. MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):781-783. [PMC free article: PMC7316318] [PubMed: 32584799]6.Fowler M, Carter RF. Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report. Br Med J. 1965 Sep 25;2(5464):740-2. [PMC free article: PMC1846173] [PubMed: 5825411]7.Maclean RC, Richardson DJ, LePardo R, Marciano-Cabral F. The identification of Naegleria fowleri from water and soil samples by nested PCR. Parasitol Res. 2004 Jun;93(3):211-7. [PubMed: 15138806]8.Gharpure R, Gleason M, Salah Z, Blackstock AJ, Hess-Homeier D, Yoder JS, Ali IKM, Collier SA, Cope JR. Geographic Range of Recreational Water-Associated Primary Amebic Meningoencephalitis, United States, 1978-2018. Emerg Infect Dis. 2021 Jan;27(1):271-274. [PMC free article: PMC7774533] [PubMed: 33350926]9.Centers for Disease Control and Prevention (CDC). Notes from the field: primary amebic meningoencephalitis associated with ritual nasal rinsing--St. Thomas, U.S. Virgin islands, 2012. MMWR Morb Mortal Wkly Rep. 2013 Nov 15;62(45):903. [PMC free article: PMC4585351] [PubMed: 24226628]10.Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007 Jun;50(1):1-26. [PubMed: 17428307]11.Güémez A, García E. Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments. Biomolecules. 2021 Sep 06;11(9) [PMC free article: PMC8469197] [PubMed: 34572533]12.Griffin JL. Temperature tolerance of pathogenic and nonpathogenic free-living amoebas. Science. 1972 Nov 24;178(4063):869-70. [PubMed: 5085984]13.Yoder JS, Straif-Bourgeois S, Roy SL, Moore TA, Visvesvara GS, Ratard RC, Hill VR, Wilson JD, Linscott AJ, Crager R, Kozak NA, Sriram R, Narayanan J, Mull B, Kahler AM, Schneeberger C, da Silva AJ, Poudel M, Baumgarten KL, Xiao L, Beach MJ. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis. 2012 Nov;55(9):e79-85. [PMC free article: PMC11307261] [PubMed: 22919000]14.Graciaa DS, Cope JR, Roberts VA, Cikesh BL, Kahler AM, Vigar M, Hilborn ED, Wade TJ, Backer LC, Montgomery SP, Secor WE, Hill VR, Beach MJ, Fullerton KE, Yoder JS, Hlsa MC. Outbreaks Associated with Untreated Recreational Water - United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):701-706. [PMC free article: PMC6023190] [PubMed: 29953425]15.Cope JR, Murphy J, Kahler A, Gorbett DG, Ali I, Taylor B, Corbitt L, Roy S, Lee N, Roellig D, Brewer S, Hill VR. Primary Amebic Meningoencephalitis Associated With Rafting on an Artificial Whitewater River: Case Report and Environmental Investigation. Clin Infect Dis. 2018 Feb 01;66(4):548-553. [PMC free article: PMC5801760] [PubMed: 29401275]16.Matanock A, Mehal JM, Liu L, Blau DM, Cope JR. Estimation of Undiagnosed Naegleria fowleri Primary Amebic Meningoencephalitis, United States1. Emerg Infect Dis. 2018 Jan;24(1):162-164. [PMC free article: PMC5749439] [PubMed: 29260676]17.Haston JC, Cope JR. Amebic encephalitis and meningoencephalitis: an update on epidemiology, diagnostic methods, and treatment. Curr Opin Infect Dis. 2023 Jun 01;36(3):186-191. [PMC free article: PMC10798061] [PubMed: 37093056]18.Vugia DJ, Richardson J, Tarro T, Vareechon C, Pannaraj PS, Traub E, Cope JR, Balter S. Notes from the Field: Fatal Naegleria fowleri Meningoencephalitis After Swimming in Hot Spring Water - California, 2018. MMWR Morb Mortal Wkly Rep. 2019 Sep 13;68(36):793-794. [PMC free article: PMC6753969] [PubMed: 31513557]19.Kemble SK, Lynfield R, DeVries AS, Drehner DM, Pomputius WF, Beach MJ, Visvesvara GS, da Silva AJ, Hill VR, Yoder JS, Xiao L, Smith KE, Danila R. Fatal Naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism. Clin Infect Dis. 2012 Mar;54(6):805-9. [PubMed: 22238170]20.Blair B, Sarkar P, Bright KR, Marciano-Cabral F, Gerba CP. Naegleria fowleri in well water. Emerg Infect Dis. 2008 Sep;14(9):1499-501. [PMC free article: PMC2603111] [PubMed: 18760036]21.Marciano-Cabral F, Cabral GA. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol. 2007 Nov;51(2):243-59. [PubMed: 17894804]22.Rehman SU, Farooq S, Tariq MB, Nasir N, Wasay M, Masood S, Karim M. Clinical manifestations and outcome of patients with primary amoebic meningoencephalitis in Pakistan. A single-center experience. PLoS One. 2023;18(11):e0290394. [PMC free article: PMC10631667] [PubMed: 37939056]23.Visvesvara GS. Amebic meningoencephalitides and keratitis: challenges in diagnosis and treatment. Curr Opin Infect Dis. 2010 Dec;23(6):590-4. [PubMed: 20802332]24.Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e68-75. [PubMed: 26582886]25.Park SY, Chang EJ, Ledeboer N, Messacar K, Lindner MS, Venkatasubrahmanyam S, Wilber JC, Vaughn ML, Bercovici S, Perkins BA, Nolte FS. Plasma Microbial Cell-Free DNA Sequencing from over 15,000 Patients Identified a Broad Spectrum of Pathogens. J Clin Microbiol. 2023 Aug 23;61(8):e0185522. [PMC free article: PMC10446866] [PubMed: 37439686]26.Bellini NK, Santos TM, da Silva MTA, Thiemann OH. The therapeutic strategies against Naegleria fowleri. Exp Parasitol. 2018 Apr;187:1-11. [PubMed: 29501696]27.Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother. 1992 Jun;29(6):719-24. [PubMed: 1506352]28.Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006 Mar-Apr;53(2):121-6. [PubMed: 16579814]29.Hannisch W, Hallagan LF. Primary amebic meningoencephalitis: a review of the clinical literature. Wilderness Environ Med. 1997 Nov;8(4):211-3. [PubMed: 11990164]30.Cárdenas-Zúñiga R, Silva-Olivares A, Villalba-Magdaleno JA, Sánchez-Monroy V, Serrano-Luna J, Shibayama M. Amphotericin B induces apoptosis-like programmed cell death in Naegleria fowleri and Naegleria gruberi. Microbiology (Reading). 2017 Jul;163(7):940-949. [PubMed: 28721850]31.Centers for Disease Control and Prevention (CDC). Investigational drug ailable directly from CDC for the treatment of infections with free-living amebae. MMWR Morb Mortal Wkly Rep. 2013 Aug 23;62(33):666. [PMC free article: PMC4604798] [PubMed: 23965830]32.Alli A, Ortiz JF, Morillo Cox Á, Armas M, Orellana VA. Miltefosine: A Miracle Drug for Meningoencephalitis Caused by Free-Living Amoebas. Cureus. 2021 Mar 04;13(3):e13698. [PMC free article: PMC8020194] [PubMed: 33833918]33.Linam WM, Ahmed M, Cope JR, Chu C, Visvesvara GS, da Silva AJ, Qvarnstrom Y, Green J. Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis. Pediatrics. 2015 Mar;135(3):e744-8. [PMC free article: PMC4634363] [PubMed: 25667249]34.Cope JR, Conrad DA, Cohen N, Cotilla M, DaSilva A, Jackson J, Visvesvara GS. Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case. Clin Infect Dis. 2016 Mar 15;62(6):774-6. [PMC free article: PMC4775347] [PubMed: 26679626]35.Ali M, Jamal SB, Farhat SM. Naegleria fowleri in Pakistan. Lancet Infect Dis. 2020 Jan;20(1):27-28. [PubMed: 31876498]36.Dorsch MM, Cameron AS, Robinson BS. The epidemiology and control of primary amoebic meningoencephalitis with particular reference to South Australia. Trans R Soc Trop Med Hyg. 1983;77(3):372-7. [PubMed: 6623596]Disclosure: Najwa Pervin declares no relevant financial relationships with ineligible companies.
Disclosure: Vidya Sundareshan declares no relevant financial relationships with ineligible companies.